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Introduction: This study’s aim was to assess economic data regard-
ing the home assistance burden for advanced non-small cell lung
cancer (NSCLC) patients in Italy.
Patients and Methods: One hundred four NSCLC patients in
second-line chemotherapy (2LC) or in supportive therapy (ST) were
enrolled in 18 Italian oncology departments and were observed for
3 months. The main caregiver’s workload was assessed monthly by
a task scale; other caregivers’ activities were also registered. Eastern
Cooperative Oncology Group performance status was assessed by
physicians, and patients completed the Lung Cancer Symptoms
(LCS) subscale. Formal caregiving time was valued according to
market prices; informal caregiving hours were valued using the
wage rate for an equivalent service. Covariance analysis was per-
formed to check for influential factors in assistance costs.
Results: The mean age of the total sample was 65.5 years, and
prevalence of males was over 80%. In over 70% of cases, the
principal caregiver was patient’s spouse, living with the patient and
not working. Principal caregiver support was the main cost item:
€2.368 in 2LC and €2.805 in ST, representing 74% of total tri-
monthly assistance costs. Regression analysis showed a positive
correlation between the severity of symptoms and the costs of
assistance.
The caregiving burden was higher in patients with bone
and/or cerebral metastases; other metastasis sites seemed to have no
impact on assistance costs.
Conclusion: Considering quality of life as the ultimate health
outcome, clinicians are challenged to contribute to a research and
policy agenda that holds burden of care in due consideration.
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Lung cancer is the leading cause of cancer-related mortalityin both men and women because lung carcinomas are
frequently diagnosed at an advanced stage, conferring a poor
prognosis. The incidence of lung cancer in Italy in 2002 was
about 37,000 new cases (65/100,000 inhabitants), and it is
forecasted to increase in the coming years (71/100,000 in-
habitants in 2010) because of the aging population.1 Non-
small cell lung cancer (NSCLC) represents roughly 80% of
all lung cancer cases.2
Many studies assessed health care costs consequent to
this disease,3–6 and all report considerable resource consump-
tion and, consequently, significant financial spending. A cost-
of-illness study conducted in Italy, observing 189 patients
with advanced NSCLC for 6 months or until death, reports a
very high burden to the National Health System for patients
treated with first- and second-line (2LC) chemotherapy, and
also for patients receiving best supportive care.7 Patients in
best supportive care were found to require the highest
monthly per-patient hospitalization costs (equal to €2298),
whereas patients in 2LC generated the greatest chemotherapy-
related adverse-event costs (up to €269 per month).
Cancer care is increasingly transferred from the inpa-
tient to the outpatient setting,8 and the burden of caring for
cancer patients, especially elderly subjects, is falling in-
creasingly on their families, with a continuous growth of
informal assistance costs.9 Few studies have examined this
issue, highlighting that informal caregiving accounts for a
substantial proportion of nonmedical costs incurred by cancer
patients.10–12
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Time and difficulties encountered in performing care-
giving tasks were evaluated among 78 family caregivers of
patients with lung cancer.13 The most time-consuming tasks
for adults, children, and spouses were emotional support,
transportation, and monitoring symptoms. The most difficult
duties were emotional support, behavioral management, mon-
itoring symptoms, and household tasks. Family caregiving is,
therefore, a resource-consuming activity necessitated by can-
cer, and it should not be forgotten when assessing the direct
costs of cancer.
The HABIT study (Home Assistance Burden in Lung
Tumor) is a longitudinal, prospective, multicenter, national
study aimed at assessing the costs of informal care in ad-
vanced NSCLC patients in Italy—either those treated with
chemotherapy or those receiving supportive therapy (ST)—
completing the information available on the direct medical
costs of this disease and providing an estimation of the costs
that the families or social security would have to support if
the informal assistance could not be provided by family
members.
PATIENTS AND METHODS
Study data were collected in 18 oncology centers all
over Italy. Centers enrolled consecutive patients treated with
2LC or ST, referring for control visits, and observed them for
3 months or until death; patients’ treatment changes were
possible during the study period, but without affecting the
initial assignment of such patients to the relevant group on
enrollment. A detailed study flow chart is shown in Figure 1.
Considering that supportive care patients can avoid controls
at the center and receive only home care or be institutional-
ized in hospices, control of enrollment was centralized, with
the aim of stimulating enrollment of supportive care subjects,
if necessary, to prevent this treatment group from being too
scarce and thus affecting the cost calculation. Exclusion
criteria were concomitant participation in clinical studies, the
absence of a regular caregiver, and the likelihood of an
unfavorable prognosis in the next 3 months. The study pro-
tocol was approved by the ethics committees of all partici-
pating centers, and patients were asked to provide their
written consent to personal data treatment before the start of
data collection. Demographic and anamnestic data were re-
ported by physicians on a paper case report form; perfor-
mance status has been assessed monthly through the Eastern
Cooperative Oncology Group (ECOG) performance scale.14
Informal caregiving time was assessed through a task scale
derived from Montgomery et al.15
The scale consisted of seven types of tasks (bathing and
dressing, feeding, housework, moving inside the house, trans-
portation, nursing, administrative tasks), and the caregivers
were instructed to assess how many hours per week they
spent performing each task. Furthermore, each main caregiver
gave information about the presence of secondary supporting
caregivers and of paid, specialized, or generic caregivers (e.g.,
nurse, physiotherapist, or housemaid). At baseline and at each
monthly interview, each patient completed the Lung Cancer
Symptoms (LCS) subscale of the FACT-L questionnaire,16–18
which is available in Italian and is suitable for assessing symp-
toms in advanced NSCLC patients.
Data were inputted into an MS SQL server database
through a Web application, which was made available only to
authorized users and consisted of html pages with online
control functions of the inputted information.
Statistical Analysis
The numbers of monthly and trimonthly hours of paid
and informal caregiving (principal plus additional family
caregivers) were calculated. To allow for 8 hours of sleep/
personal care, a limit of 16 hours per day (112 per week) was
imposed for any caregiver.
In the longitudinal analysis, patients were maintained in
their respective initial assignment groups, and we analyzed
the modifications of variables concerning patients’ clinical
status and assistance needs, from baseline to the end of
observation period, in the two treatment groups.
Regarding patients’ clinical situations (ECOG and LCS
subscale of the FACT-L questionnaire), data were analyzed
according to literature-based methods or to the scale manuals
prepared by the authors of the questionnaires. The longitudi-
nal analysis within groups described the scale scores at single
visits and the variations in disease-specific symptoms, and
each patient’s performance status change between the base-
line visit and the last assessment. Missing items of the LCS
FACT-L scale were replaced (but only if at least four items
were answered) by using the following formula: “Sum of
items score  7/number of answered items.” Patients with a
score variation of 2 or more were considered improved,
whereas a score variation of less than 2 meant aggravation of
the patient’s condition.19
Cost Analysis
For each identified category, literature-based unit costs
were set on resources, expressed in physical units (hours of
assistance). For fee-based assistance, the relevant national
FIGURE 1. Study flow chart.
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tariff was applied to each service. Regarding informal care, a
replacement cost was applied, assessing values to physical
units on the basis of hourly costs of the closest professionals
to the assistance activities performed by caregivers—nurse,
for health care–type services; home help, for housework—
referring to the relevant national collective agreement. Unit
costs and the relevant sources are reported in Table 1.
Identification of Cost Determinants
Factors, increasing the assistance need and respective
costs, were identified by means of several covariance analy-
ses, using the following variables as covariate values: pa-
tient’s age, type of therapy, cancer stage, time elapsed from
first diagnosis, caregiver’s living situation (with the patient or
not), ECOG scores, and LCS scores. For patient’s age, type of
therapy, and caregiver’s home situation, the correlation be-
tween costs and initial value was analyzed. For the LCS
subscale of the FACT-L questionnaire, and for the ECOG
scale, the correlations of costs with initial score and costs
with score difference between first and last assessment were
analyzed.
A multiple-regression model was applied to evaluate
which of the variables described above significantly predicts
the assistance costs; these were converted into logarithms to
normalize the data.
An additional analysis was conducted to investigate the
relation between the presence and localization of metastasis
and the cost of the informal care provided by the principal
caregiver. Sample was stratified according to metastasis pres-
ence and type, regardless of the therapy, and assistance costs
were compared between groups, also excluding costs related
to domestic activities, which might be performed by the
caregiver independently of the presence of a cancer patient.
RESULTS
From February to June 2004, 104 dyads consisting of
patients with advanced NSCLC and their family caregivers
were enrolled in 18 oncology centers. No significant differ-
ences were found in the demographic variables in the two
groups, 2LC and ST, as shown in Table 2. Our sample had a
mean age of 60 years, with a wide range of 35 to 82 years;
the prevalence of males was more than 80% in both groups.
The large majority of subjects were not on paid job at the time
of enrollment, and only five subjects declared that they had
ceased working because of the disease before the study’s
start, whereas the others retired for reasons different from the
disease under consideration. Eighty-two percent of patients
had stage IV NSCLC with prevalent bony and cerebral
metastases, especially in ST patients. During the study pe-
riod, 53% of patients in 2LC changed therapy, whereas only
6% of ST patients switched to chemotherapy. Generally, the
main caregiver was the patient’s spouse, usually the wife,
living with the patient and not working in over 70% of cases.
Only one ST patient changed caregivers during the study
period (Table 3).
Patients’ performance statuses declined in both groups
throughout the study. During the 3 months of observation, 12
patients died in both groups: 22% of initial 2LC cases and
24.5% of initial ST cases. Table 4 shows the deterioration of
performance status in both patient groups; at baseline, the
majority of patients were asymptomatic or fully ambulatory
regardless of the treatment, whereas after 3 months, 5 and
12% of patients in 2LC and ST, respectively, were bedridden.
Also, the seriousness of symptoms worsened during the study
period. Figure 2 shows the percentages of patients with
TABLE 1. Unit Costs and Relevant Sources
€/hour Reference
Nurse 34.8 National Federation of Colleges of Nursing
(www.ipasvi.it)
Physiotherapist 20.66 Ministerial Decree of July 22, 1996.
Outpatient National Tariffs, Official Gazette
n. 216, November 14, 1996
Housekeeper 4.33 National Housekeepers Contract. CCNL
8.3.2001, art 34
TABLE 2. Patient Characteristics
2LC ST Total
No. of patients 55 49 104
Percent male 82 90 86
Age (yr) 62.8 (9.4) 68.5 (9.3) 65.5 (9.8)
Working situation (%)
Working 13 6 10
Not working 87 94 90
Stage (%)
IIIb 18 18 18
IV 82 82 82
Months since first diagnosis 17.1 (14.3) 27.5 (46.1) 22.0 (33.5)
Previous surgery: yes/no (%) 33/67 31/69 32/68
Metastasis (%)
Bone or cerebral 40 54 47
Other 42 25 34
Absent 18 21 19
2LC, second-line chemotherapy; ST, supportive therapy.
TABLE 3. Principal Caregiver Characteristics
2LC ST Total
Percent female 72 76 74
Age (yr) 53.1 (14.6) 56.7 (14.0) 54.7 (14.4)
Living situation (%)
With the patient 91 77 84
Without the patient 9 22 15
Missing — 2 1
Degree of relationship
with patient (%)
Spouse 76 65 70
Son/daughter 15 21 18
Other 9 14 12
Working situation (%)
Working 28 26 27
Not working 72 74 73
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improved, worsened, or unvaried conditions at last interview
in comparison with the baseline, in the two treatment groups.
Similar percentages of patients (37% in both groups)
worsened or improved (7% in 2LC and 6% in ST) after 3
months; the high percentage of missing assessments is largely
attributable to patient deaths.
One hundred one patients were eligible for the informal
caregiving burden. Two patients were excluded from the cost
analysis because of insufficient information, and one was
excluded because he was assisted by a professional caregiver
for about 145 hours per week, representing the unique case of
this type of assistance in our sample.
The informal care given by the main caregiver was the
main assistance cost item (Figure 3), €2.368 2LC and €2.805
ST, representing 74% of total assistance costs in both groups
during the study period. The analysis of monthly assistance
costs showed constant increases, except for the cost at the
third month of observation, in the supportive care patients’
group (Figure 4).
The regression analysis, performed to identify the de-
terminants of costs, did not show statistically significant
correlations between the three monthly costs and the vari-
ables considered in our model, except for caregiver’s living
situation and score variations on the LCS subscale. Assis-
tance costs were higher when caregivers did not live with
patients (p  0.0001), and score variations on the LCS
subscale were in inverse relation to the assistance costs; that
is, score decreases correspond to cost increases (p  0.0001).
LCS score decreases correspond to worsened symptoms per-
ceived by patients; this correlation associates a patient’s
aggravation with an increased need for assistance and, con-
sequently, with higher costs.
Figure 5 shows assistance costs for the whole sample,
stratified by presence and type of metastasis, regardless of the
type of treatment administered to patients. Cerebral and/or
bony metastases caused, on each monthly check, significantly
higher assistance costs to the main caregivers (p  0.0001).
DISCUSSION
The results of the HABIT study show that advanced
NSCLC patients require extensive assistance from family
TABLE 4. Eastern Cooperative Oncology Group Performance
Status at Baseline and Last Observation: Percentage of Patients
in the Different Scores
Baseline (%) Last Observation (%)
Scores 2LC ST 2LC ST
0–1 75 69 42 47
2–3 25 27 31 16
4 — 4 5 12
5 — — 22 25
2LC, second-line chemotherapy; ST, supportive therapy. Score key: 0, asymptom-
atic; 1, symptomatic but fully ambulatory; 2, symptomatic and in bed less than 50% of
the day; 3, symptomatic and in bed more than 50% of the day; 4, bedridden; 5, dead.
FIGURE 2. Lung Cancer Symptoms subscale. Symptoms
changes between baseline (T0) and last observation (T3).
FIGURE 3. Average trimonthly costs per patients in the two
treatment groups.
FIGURE 4. Monthly assistance costs per caregiver type. The
nursing component of principal caregiver activities is pre-
sented separately from the other tasks.
FIGURE 5. Monthly informal assistance cost (principal care-
giver tasks, excluding housekeeping) per metastasis presence
and localization.
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caregivers. Caregiving burden was associated with household
tasks, supporting patients in daily living activities, nursing
care, managing transportation, and illness-related finances.
The nature of informal caregiving activities influenced
the costs in our study, because the time devoted to the
different tasks was valued according to a replacement cost
method, which estimates what the financial burden would be
if the same activities were performed by paid professionals.
According to this perspective, some tasks are time consuming
as household activities but have a lower market value than
others, such as nursing ones, which are less time intensive.
Assistance costs tend to increase with time in both
chemotherapy and supportive care patients. Performance sta-
tus variation measured through the ECOG scale did not show
any influence on assistance costs, whereas the regression
analysis showed a correlation between increases in symptom
severity as perceived by patients (LCS scores) and the in-
creases in assistance costs. It should be noted that our sample
comprised patients enrolled at oncology centers who were
still able to go to the hospitals for routine visits; terminally ill
or fully bedridden patients could not be represented in this
sample, because their condition prevented them from refer-
ring to the centers, as reflected by the low percentage of
patients with ECOG scores of 4 (bedridden) at any assess-
ment time.
The LCS subscale is not only a validated patient in-
strument with reliability in detecting clinically significant
changes in NSCLC-related symptoms; it is also a good
predictor of assistance need and costs, and it may have a role
in clinical practice. Observed changes in patient-reported
outcomes may facilitate patient–physician communication,
especially in patients with declining outcomes, and it has
been shown that effective patient–physician communication
is associated with lower patient distress and improved phys-
ical outcomes.20 Our experience suggests that the LCS sub-
scale may provide additional information about a patient’s
status and need for assistance that is not provided by tradi-
tional clinical parameters of function; this information could
be useful to clinicians to enlighten caregivers as to the future
burden of the disease.
It should be noted that our sample was representative of
the patients referring to oncology centers for regular visits
therefore patients that despite we introduced very few enroll-
ment criteria.
Caregiving costs were higher when the main caregivers
did not live with the patients; this is probably because spouse
caregivers, mostly women in our sample, are more likely to
attend normally to the needs of their spouses,21 and they
might not consider caregiving to be solely related to the
disease as nonspouse caregivers would.
Caregiving burdens were constantly higher at all obser-
vation times in patients with bony and/or cerebral metastases;
other metastasis localizations seemed to have no impact on
assistance costs.
Our model was able to explain about one third of the
assistance cost variability, showing that there is room for
improvement in the detection of caregiver burden compo-
nents. A limitation of our task scale is that we did not include
emotional support among the task categories, even though
previous studies13,22 have shown that this was the most
time-consuming task. Our choice was based on our objective
of estimating a possible replacement cost for informal care,
and we believe that emotional support is a caring activity that
a family could not successfully delegate to a professional
caregiver being paid for his or her time.
The increasing responsibilities of families to provide
care in the face of limited external support, and the conse-
quences of that caregiving for patients and families, are
raising serious concerns among clinicians. Considering qual-
ity of life as the ultimate health outcome, clinicians are
challenged to contribute to a research and policy agenda that
holds the burden of care in due consideration. It has been
shown that the severity of symptoms triggers the assistance
cost; therefore, in evaluating new and more effective cancer
therapies to preserve quality of life, it is also worth assessing
the impact of home assistance, whether it is provided by
family members or by paid professionals.
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